<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03101644</url>
  </required_header>
  <id_info>
    <org_study_id>UCL-LB-02</org_study_id>
    <nct_id>NCT03101644</nct_id>
  </id_info>
  <brief_title>Optimization of Darunavir Therapy and Dosage Recommendations</brief_title>
  <official_title>Optimization of Darunavir Therapy Through Population Pharmacokinetic Modeling, Simulations and Dosage Guidelines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess and characterize the variability observed in the response to darunavir
      therapy, an antiretroviral medication used against the Human Immunodeficiency Virus (HIV).
      More specifically, it aims to quantify variations in the drug's blood concentrations and
      determine the sources of such variability, both genetic and non-genetic. In light of this
      information, current dosage guidelines will then be reviewed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data will be used to create a population pharmacokinetic model. Inter- and intra-individual
      pharmacokinetic variability will be quantified and linked to patient-specific covariates,
      both genetic and non-genetic in nature. Pharmacokinetic-pharmacodynamic relationships will be
      established, linking drug exposure to efficacy (as measured by CD4 cell count and viral load
      reduction) and toxicity (as measured by frequency and degree of adverse events). Simulations
      will be conducted for specific patient profiles and current dosage guidelines reviewed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 23, 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Darunavir clearance</measure>
    <time_frame>Up to 18 months (blood sampling for PK once at each visit, three visits per patient over the study period)</time_frame>
    <description>Assessment of darunavir whole-body clearance and inter-compartmental clearance through population pharmacokinetic methods</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Darunavir volume of distribution</measure>
    <time_frame>Up to 18 months (blood sampling for PK once at each visit, three visits per patient over the study period)</time_frame>
    <description>Assessment of darunavir volume of distribution through population pharmacokinetic methods</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Darunavir absorption rate</measure>
    <time_frame>Up to 18 months (blood sampling for PK once at each visit, three visits per patient over the study period)</time_frame>
    <description>Assessment of darunavir absorption rate through population pharmacokinetic methods</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Darunavir area under the concentration-time curve (AUC)</measure>
    <time_frame>Up to 18 months (blood sampling for PK once at each visit, three visits per patient over the study period)</time_frame>
    <description>Assessment of darunavir area under the concentration-time curve through population pharmacokinetic methods</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Darunavir maximum plasma concentration (Cmax)</measure>
    <time_frame>Up to 18 months (blood sampling for PK once at each visit, three visits per patient over the study period)</time_frame>
    <description>Assessment of darunavir maximum plasma concentration through population pharmacokinetic methods</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events/laboratory abnormalities</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Assessment of the frequency of adverse events or laboratory abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in viral load</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Assessment of the change in viral load (HIV copies/ml of blood)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood Cluster of Differentiation 4 (CD4+) T lymphocyte count</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Assessment of the change in blood CD4+ T lymphocyte count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ritonavir/cobicistat AUC</measure>
    <time_frame>Up to 18 months (blood sampling for PK once at each visit, three visits per patient over the study period)</time_frame>
    <description>Assessment of the pharmacokinetic booster (either ritonavir or cobicistat, depending on the subject) AUC through population pharmacokinetic methods</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Human Immunodeficiency Virus I Infection</condition>
  <arm_group>
    <arm_group_label>Darunavir</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients treated with darunavir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir</intervention_name>
    <description>The investigated drugs are Prezista (darunavir 600 mg twice-daily or 800 mg once-daily) and Rezolsta (darunavir 800 mg/cobicistat 150 mg once-daily)</description>
    <arm_group_label>Darunavir</arm_group_label>
    <other_name>Prezista</other_name>
    <other_name>Rezolsta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Capable of giving informed consent

          -  HIV-positive

          -  Routinely followed at the Cliniques universitaires Saint-Luc

          -  Treated with darunavir

        Exclusion Criteria:

        - N/A
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leila Belkhir, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques universitaires Saint-Luc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laure Elens, PhD</last_name>
    <phone>+32 2 764 72 27</phone>
    <email>laure.elens@uclouvain.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cliniques universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leila Belkhir, MD</last_name>
      <phone>+32 2 764 21 22</phone>
      <email>leila.belkhir@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Leila Belkhir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard Vandercam, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Cyr Yombi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Vincent, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2017</study_first_submitted>
  <study_first_submitted_qc>March 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2017</study_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université Catholique de Louvain</investigator_affiliation>
    <investigator_full_name>Laure Elens</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darunavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

